TDI is interested in pursuing theranostic development programs beyond our primary cancer focus, with pharmaceutical or biotech partners that are prepared to fund such programs. Theranostic partnerships will be approached in a solution-oriented and product-focused way, with a clear understanding of strategy and goals. To each partnership, TDI contributes research and product development expertise, as well as access to our proprietary technologies for validation of protein biomarkers. We will also incorporate these biomarkers into Isonostic™ products that provide improved information to the clinician and patient.

Our goal is to be a partner of choice for the development of new diagnostics and theranostic assays based on the resolution of protein isoforms. We will prioritize opportunities to participate in the development of highly differentiated products that address significant diagnostic challenges and offer superior commercialization potential.

If you have an idea or proposal that you wish to discuss with us, please contact:

bizdev@targetdiscovery.com
Toll Free: (877) 834-4620